Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Koch

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Journal of Medicinal Chemistry|December 6, 2014
Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
Bioorganic & Medicinal Chemistry|October 22, 2013
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseasesPierre Koch, Rhalid Akkari, Andreas Brunschweiger, et al.
Journal of Medicinal Chemistry|December 16, 2016
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3Felix Muth, Ahmed El-Gokha, Francesco Ansideri, et al.
Journal of Medicinal Chemistry|February 27, 2015
Correction to Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
ACS Medicinal Chemistry Letters|October 18, 2019
Pyridinylimidazoles as GSK3β Inhibitors: The Impact of Tautomerism on Compound Activity via Water NetworksFabian Heider, Tatu Pantsar, Mark Kudolo, et al.
Bioorganic & Medicinal Chemistry|September 24, 2016
8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitorsAndreas Brunschweiger, Pierre Koch, Miriam Schlenk, et al.
Journal of Medicinal Chemistry|December 22, 2011
Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinasesBassam Abu Thaher, Martina Arnsmann, Frank Totzke, et al.
Frontiers in Chemistry|July 13, 2018
Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic ActivityPierre Koch, Andreas Brunschweiger, Vigneshwaran Namasivayam, et al.
ACS Omega|August 9, 2018
Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3Francesco Ansideri, Joana T Macedo, Michael Eitel, et al.
Journal of Medicinal Chemistry|July 2, 2021
Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β InhibitorsStanislav Andreev, Tatu Pantsar, Roberta Tesch, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Journal of Medicinal Chemistry|December 6, 2014
Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
Bioorganic & Medicinal Chemistry|October 22, 2013
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseasesPierre Koch, Rhalid Akkari, Andreas Brunschweiger, et al.
Journal of Medicinal Chemistry|December 16, 2016
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3Felix Muth, Ahmed El-Gokha, Francesco Ansideri, et al.
Journal of Medicinal Chemistry|February 27, 2015
Correction to Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseasesFelix Muth, Marcel Günther, Silke M Bauer, et al.
ACS Medicinal Chemistry Letters|October 18, 2019
Pyridinylimidazoles as GSK3β Inhibitors: The Impact of Tautomerism on Compound Activity via Water NetworksFabian Heider, Tatu Pantsar, Mark Kudolo, et al.
Bioorganic & Medicinal Chemistry|September 24, 2016
8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitorsAndreas Brunschweiger, Pierre Koch, Miriam Schlenk, et al.
Journal of Medicinal Chemistry|December 22, 2011
Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinasesBassam Abu Thaher, Martina Arnsmann, Frank Totzke, et al.
Frontiers in Chemistry|July 13, 2018
Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic ActivityPierre Koch, Andreas Brunschweiger, Vigneshwaran Namasivayam, et al.
ACS Omega|August 9, 2018
Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3Francesco Ansideri, Joana T Macedo, Michael Eitel, et al.
Journal of Medicinal Chemistry|July 2, 2021
Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β InhibitorsStanislav Andreev, Tatu Pantsar, Roberta Tesch, et al.
Pageof 8